As of May 13, 2025, the Regeneron Pharmaceuticals stock's PE ratio is 13.75. This takes into account the latest EPS of $41.77 and stock price of $574.16. The PE ratio marks a decrease of 34% from its last 4 quarters average of 20.7.
The PE ratio of Regeneron Pharmaceuticals has averaged 29.12 over the last ten years. The current P/E ratio of 13.75 is 53% lower than the historical average. Looking back at the last ten years, REGN's PE ratio peaked in the Jun 2015 quarter at 117.27, when the price was $510.13 and the EPS was $4.35. The lowest point was in the Dec 2021 quarter, when it reached 8.27 with a price of $631.52 and an EPS of $76.4.
Maximum annual increase: 201.25% in 2013
Maximum annual decrease: -51.21% in 2016
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 17.42 | -26.53% | $712.33 | $40.9 |
2023 | 23.71 | 33.13% | $878.29 | $37.05 |
2022 | 17.81 | 115.36% | $721.49 | $40.51 |
2021 | 8.27 | -44.12% | $631.52 | $76.4 |
2020 | 14.8 | -23.59% | $483.11 | $32.65 |
2019 | 19.37 | 17.47% | $375.48 | $19.38 |
2018 | 16.49 | -50.57% | $373.5 | $22.65 |
2017 | 33.36 | -22.29% | $375.96 | $11.27 |
2016 | 42.93 | -51.21% | $367.09 | $8.55 |
2015 | 87.99 | -27.94% | $542.87 | $6.17 |
2014 | 122.1 | 87.64% | $410.25 | $3.36 |
2013 | 65.07 | 201.25% | $275.24 | $4.23 |
2012 | 21.6 | N/A | $171.07 | $7.92 |
2011 | N/A | N/A | $55.43 | -$2.45 |
2010 | N/A | N/A | $32.83 | -$1.26 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | 15.18 | -12.86% | $634.23 | $41.77 |
Dec 2024 | 17.42 | -28.34% | $712.33 | $40.9 |
Sep 2024 | 24.31 | -6.75% | $1,051.24 | $43.24 |
Jun 2024 | 26.07 | -2.18% | $1,051.03 | $40.32 |
Mar 2024 | 26.65 | 12.4% | $962.49 | $36.12 |
Dec 2023 | 23.71 | 7.67% | $878.29 | $37.05 |
Sep 2023 | 22.02 | 23.22% | $822.96 | $37.38 |
Jun 2023 | 17.87 | -15.07% | $718.54 | $40.21 |
Mar 2023 | 21.04 | 18.14% | $821.67 | $39.06 |
Dec 2022 | 17.81 | 30.09% | $721.49 | $40.51 |
Sep 2022 | 13.69 | 23.56% | $688.87 | $50.31 |
Jun 2022 | 11.08 | 19.01% | $591.13 | $53.37 |
Mar 2022 | 9.31 | 12.58% | $698.42 | $74.98 |
Dec 2021 | 8.27 | -9.42% | $631.52 | $76.4 |
Sep 2021 | 9.13 | -3.69% | $605.18 | $66.28 |
REGN's current PE ratio is lower than its 3, 5 and 10-year averages.
REGN's PE ratio stands lower than its peer stocks JNJ and NVS, but it is higher than BIIB's. Regeneron Pharmaceuticals is currently trading at a lower PE ratio (13.75) than its peers average of 17.39.
Stock name | PE ratio | Market cap |
---|---|---|
BIIB Biogen Inc | 12.12 | $18.05B |
REGN Regeneron Pharmaceuticals Inc | 13.75 | $61.99B |
JNJ Johnson & Johnson | 16.38 | $357.16B |
NVS Novartis AG | 16.59 | $209.31B |
AMGN Amgen Inc | 24.48 | $145.42B |
ALNY Alnylam Pharmaceuticals Inc | N/A | $34.8B |
REGN stock has a price to earnings ratio of 13.75 as of May 13, 2025.
The 3-year average price to earnings ratio for REGN stock is 19.74.
The 5-year average price to earnings ratio for REGN stock is 17.13.
Over the last ten years, the quarterly PE ratio reached its highest level at 117.27 in the Jun 2015 quarter.
REGN's price to earnings ratio is currently 53% below its 10-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (May 13, 2025), Regeneron Pharmaceuticals's share price is $574.16. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $41.77. Therefore, Regeneron Pharmaceuticals's PE ratio for today is 13.75. PE RATIO(13.75) = STOCK PRICE($574.16) / TTM EPS($41.77)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.